Compare OI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | MESO |
|---|---|---|
| Founded | 1903 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | OI | MESO |
|---|---|---|
| Price | $15.43 | $18.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $16.29 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 2.3M | 206.1K |
| Earning Date | 11-04-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,455,000,000.00 | $17,198,000.00 |
| Revenue This Year | $1.41 | $465.44 |
| Revenue Next Year | $1.99 | $75.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 191.39 |
| 52 Week Low | $9.23 | $9.61 |
| 52 Week High | $16.04 | $22.00 |
| Indicator | OI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 60.70 |
| Support Level | $13.01 | $16.43 |
| Resistance Level | $14.60 | $17.65 |
| Average True Range (ATR) | 0.49 | 0.61 |
| MACD | 0.17 | 0.25 |
| Stochastic Oscillator | 99.46 | 73.73 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.